A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
-
- STATUS
- Recruiting
-
- days left to enroll
- 67
Summary
Brexpiprazole is a drug being studied as a possible treatment for borderline personality disorder (BPD). It was first approved in the United States (10 July 2015) for the treatment of schizophrenia and as an adjunctive therapy (add-on therapy) to antidepressants for the treatment of major depressive disorder. The reason for this study is to find out about the potential benefits and safety of brexpiprazole in subjects with a diagnosis of BPD.
Details
| Condition | Borderline Personality Disorder, Mood Disorders |
|---|---|
| Clinical Study Identifier | TX247004 |
| Last Modified on | 9 September 2020 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer